Title: The effect of exenatide on intracranial pressure in Idiopathic Intracranial Hypertension, IIH Pressure: A Randomised Clinical Trial

Authors: James L. Mitchell,[1,2,3] Hannah S. Lyons,[1,2] Jessica K. Walker,[1] Andreas Yiangou,[1,2] Olivia Grech,[1] Zerin Alimajstorovic,[1] Nigel H. Greig,[4] Yazhou Li,[4] Georgios Tsermoulas,[1,5] Kristian Brock,[6] Susan P. Mollan,[1,7] Alexandra J. Sinclair[1,2],*

Affiliations:

[1]University of Birmingham, Institute of Metabolism and Systems Research; Birmingham, United Kingdom.

[2]University Hospitals Birmingham NHS Foundation Trust, Department of Neurology; Birmingham, United Kingdom.

[3]Academic Department of Military Rehabilitation, Defence Medical Rehabilitation Centre; Stanford Hall, United Kingdom.

[4]Drug Design & Development Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health; Baltimore, USA.

[5]University Hospitals Birmingham, Department of Neurosurgery; Birmingham, United Kingdom.

[6]University of Birmingham, Cancer Research UK Clinical Trials Unit; Birmingham, United Kingdom.

[7]University Hospitals Birmingham NHS Foundation Trust Birmingham Neuro-Ophthalmology; Birmingham, United Kingdom.

*Corresponding author. Email: a.b.sinclair@bham.ac.uk

One Sentence Summary: Exenatide, a GLP-1 receptor agonist significantly reduced intracranial pressure in patients with idiopathic intracranial hypertension with acute and chronic dosing.

Abstract:

Therapeutics to reduce intracranial pressure (ICP) are an unmet need. Pre-clinical data has demonstrated a novel strategy to lower ICP using glucagon-like peptide-1 receptor (GLP-1R) signaling. Here, we translate these findings into patients by conducting a randomized, placebo controlled, double-blind trial to assess the effect of exenatide, a GLP-1R agonist, on ICP in idiopathic intracranial hypertension (IIH). Telemetric ICP catheters enabled long-term ICP monitoring. The trial enrolled adult women with active IIH (ICP >25 cmCSF and papilloedema) who receive subcutaneous exenatide or placebo. The primary outcome was ICP at 2.5 hours, 24 hours and 12 weeks and alpha set a priori at less than 0.1. Among the 16 women recruited, 15

completed the study (mean age 28 ± 9, body mass index 38.1 ± 6.2 kg/m², ICP 30.6 ± 5.1 cmCSF). Exenatide significantly and meaningfully lowered ICP at 2.5 hours -5.7 ± 2.9 cmCSF (p=0.048); 24 hours of -6.4 ± 2.9 cmCSF (p=0.030); and 12 weeks -5.6 ± 3.0 cmCSF (p=0.058). No serious safety signals were noted. This data provides confidence to proceed to a phase 3 trial in IIH and highlights the potential to utilise GLP-1R agonist in other conditions characterised by raised ICP.

INTRODUCTION

Glucagon-like peptide-1 (GLP-1) is a gut neuropeptide secreted by the distal small intestine in response to a meal.[1] GLP-1 receptor agonists are existing therapeutic agents used to in the treatment of diabetes. GLP-1 stimulates glucose-dependant insulin secretion and inhibits glucagon release, thereby lowering blood glucose but not causing hypoglycaemia. [2] GLP-1 receptor agonists also signal at the hypothalamus to regulate satiety and weight.[3] This has led to GLP-1 receptor agonists being licensed to promote weight loss in the setting of obesity.[4]

Relevant to this trial is the role of GLP-1 receptor agonists in regulating fluid secretion. GLP-1 receptor agonists have been shown to reduce sodium reabsorption and promote diuresis through actions in the renal proximal tubule.[5, 6] GLP-1 receptors are expressed in the choroid plexus, the predominant cerebrospinal fluid secreting structure in the brain.[7, 8] Our preliminary data has shown that GLP-1 receptor agonism reduces CSF secretion and intracranial pressure (ICP) in an *in vivo* rodent model with elevated ICP.[7] The reduction in ICP was of a greater magnitude to that observed with the commonly used drugs in IIH.[9]

Idiopathic Intracranial Hypertension (IIH) is characterized by increased intracranial pressure ICP with no identifiable cause. Recent weight gain is the major risk factor for development of the condition and its occurrence is most commonly observed in women of reproductive age with obesity.[10, 11] Weight loss is disease modifying and if maintained can induce remission.[12, 13] As the incidence of IIH is rising[14-16] in line with global obesity trends,[17] targeted treatments are an unmet clinical need.

Visual loss is observed in greater than 90% of those with IIH[18] with up to 25% suffering severe permanent blindness.[19] Chronic disabling headaches occur in the majority and have adverse impact on quality of life.[20, 21] Cognitive deficits linked to raised ICP have been documented.[22] Currently, there is no licenced therapy for IIH.[23] The most commonly used off-label medicine is acetazolamide, but due to side effects and treatment failures new therapies are needed. Patient groups have highlighted the importance of prioritising novel targeted treatments for IIH.[24]

The aim of this study was to translate the pre-clinical data demonstrating efficacy of GLP-1 receptor signalling to reduce ICP into patients with raised ICP by conducting a randomized, placebo controlled, double-blind trial in IIH. The trial aimed to evaluate both acute effects on ICP as well as effects over a 3-month time horizon.

RESULTS

Patients

Between November 1st, 2017, and September 17th, 2018, 18 participants were screened, 16 enrolled and 15 randomly assigned to either the exenatide group (n=7) or the placebo group (n=8) (Figure 1).

Adherence to the Protocol

One participant was withdrawn before randomization due to disease progression requiring urgent cerebrospinal fluid shunting (Figure 1). All randomised patients completed the 12-week duration of the trial, however one patient experienced telemeter failure prior to week 12, therefore ICP data was not recorded, and all other data for week 12 was collected for this patient. There was full adherence to protocol with no cross over and no significant protocol deviation, except blood tests for pharmacokinetics which were missed on four occasions.

Demographics and baseline characteristics

Baseline characteristics confined a cohort of patients with active IIH (Supp. table 1). Age, body mass index (BMI) and ICP at baseline were well-matched between groups. Median (IQ range) time from surgery to baseline visit was 10 days (16.5) (Supp. table 1). At baseline there was a significant difference in monthly headache days between arms, exenatide 21.6 (5.2) (mean (SD)) and placebo 10.3 (8.5), p=0.009; there was also a significant difference in perimetric mean deviation, exenatide -0.6 (1.0)dB (mean (SD) and placebo -2.7 (1.9) dB, p=0.025 (Supp. table 2).

Primary outcome measure

The primary clinical outcome was the difference in ICP between exenatide and placebo, as measured by telemetric ICP monitoring at 2.5 hours, 24 hours and 12 weeks. The difference in ICP between arms at 2.5 hours was -4.2 (2.1) (mean (SD) mmHg), p=0.048, and at 24 hours was -4.7 (2.1), p=0.030. The effect was sustained at 12 weeks with an ICP difference of -4.1 (2.2), p=0.058. (Table 1, Figure 2) This was equivalent to 5.7 (2.9) cmCSF (Mean (SD)) at 2.5 hours, 6.4 (2.9) cmCSF at 24 hours and 5.6 (3.9) cmCSF at 12 weeks.

	ICP at baseline mean (SD)	ICP at time point mean (SD)	Difference in ICP baseline to time point mean (SD); 95%CI, p	Difference in ICP between arms at time point mean (SE); 95%CI, p
ICP 2.5 hours (mmHg)				
Exenatide (n=7)	22.3 (3.6)	21.8 (3.4)	-0.5 (1.9); (-2.3, 1.2), p=0.485	-4.2 (2.1); (-8.4, 0.0), p=0.048

Placebo (n=8)	24.6 (4.1)	26.0 (3.4)	1.4 (1.8); (-0.1, 2.9), p=0.060	
ICP 24 hours (mmHg)				
Exenatide (n=7)	22.3 (3.6)	18.9 (5.3)	-3.4 (3.5); (-6.6, -0.2), p=0.042	
Placebo (n=8)	24.6 (4.1)	23.5 (4.5)	-1.0 (3.3); (-3.8, 1.7), p=0.406	-4.7 (2.1); (-8.8, -0.5), p=0.030
ICP 12 weeks (mmHg)				
Exenatide (n=7)	22.3 (3.6)	21.4 (4.0)	-0.9 (2.7); (-3.3, 1.6), p=0.410	
Placebo (n=7)	24.6 (4.1)	26.0 (4.4)	1.2 (5.1); (-3.5, 5.8), p=0.565	-4.1 (2.2); (-8.4, 0.1), p=0.058

Table 1. Primary outcome measures. ICP, intracranial pressure.

Secondary clinical outcomes

The key secondary outcome was monthly headache days which reduced significantly in the exenatide arm, -7.7 (9.2) days (mean (SD), p=0.069 compared to the placebo arm -1.5 (4.8) days, p=0.404 (Figure 3) and changes in monthly analgesia days showed a trend to improvement in the exenatide arm (Figure 3, Supp. Table 2). There was no significant change in headache severity. Headache disability measured by HIT-6 was significantly higher in the exenatide arm at baseline 62.9 (3.2) vs 55.8 (6.9), (mean (SD)), p=0.041, there was no significant change over the course of the trial (Figure 3, Supp. table 2).

Vision

Visual acuity significantly improved in the exenatide arm compared to the placebo arm -0.1 (0.05) LogMar units, p=0.036. There was no significant change in perimetric mean deviation, difference between arms 1.0 (0.8) dB, p=0.188. Optical Coherence Tomography Retinal Nerve Fibre Layer (OCT RNFL) did not change significantly between arms, -40.2 (47.2) µm, p=0.396. (Figure 3, Supp. table 2).

Intra-ocular pressure

There was no significant change in intra-ocular pressure, difference between arms -0.1 (1.1), p=0.910 (Supp. table 2).

Quality of life

Analysis of quality of life, utilizing the SF36, showed no significant changes in either the physical or mental component scores (Supp. table 2).

Body Mass Index

BMI in the placebo arm was 38.6 (4.7) kg/m^2 and 38.1(4.9) kg/m^2 at 12 weeks, whereas in the exenatide arm baseline was 37.6 (7.9) kg/m^2 and 37.5 (7.4) kg/m^2 at 12 weeks. There was no significant difference in BMI between arms at 12 weeks, p=0.854 (Figure 3, Supp. table 2).

Safety bloods

No significant changes were seen in the safety monitoring bloods (Supp. table 3).

Adverse Events

12 adverse events were reported during the trial. 8 adverse events occurred in the exenatide arm, 7 of which were nausea related to exenatide initiation. 4 adverse events occurred in the placebo arm. One unrelated serious adverse event, thyrotoxicosis, was reported in the placebo arm. No patients withdrew due to adverse events (Supp. table 4).

Anti-exenatide Antibodies

No anti-exenatide antibodies were detected in samples collected at baseline. In total 2 of the 7 patients on exenatide developed antibodies by week 12. At week 2 one patient had antibodies present (> 0.1 µg/ml), these were also present at 12 weeks (> 0.1 µg/ml). A further patient was noted to have antibodies at 12 weeks (>1.0 µg/ml).

Drug concentrations measurements

The 2 patients with anti-exenatide antibodies at 12 weeks had higher (3- and 6-fold higher) than predicted exenatide concentrations at 12 weeks and were excluded from the 12 weeks data analysis. At baseline, week 2 and week 12, there was a sharp increase in exenatide concentrations in patient serum at 2.5 hours following subcutaneous administration of exenatide. This was followed by a sharp decline in peptide concentrations at 6 hours. The mean exenatide concentrations at 2.5 hours are higher at baseline than at week 2 and week 12 (575.4, 380.7 and 205.4 pg/ml respectively), which is expected as 20 µg of exenatide was administered at baseline, compared to 10 µg administered at the week 2 and 12 (Supp. table 5, Supp. figure 1). The number of participants was insufficient for meaningful analysis of the relationship between pharmacokinetics and efficacy.

Glucose and Insulin

No hypoglycaemia was encountered during the trial. There was no significant difference in fasted glucose and fasted insulin between the two trial arms at 12 weeks (Supp. table 6, Supp. figure 2).

Vital Signs

Blood pressure and heart rate were stable during the trial, mean arterial pressure was lower at 12 weeks in the exenatide group compared to placebo, -6.7mmHg (3.6), p=0.088, but there was no significant change within arms between baseline and 12 weeks (Supp. table 2).

Post Hoc Analysis - Exploratory ICP

We looked in more detail at the changes in ICP in the first 2.5 hours following drug administration. ICP was significantly lower recordings over time points 90-120 minutes (-4.6 (2.1) (mean (SD)) mmHg p=0.028) and 120-150 minutes (-4.2 (2.1) (mean (SD)) mmHg, p=0.042) (Supp. table 7, figure 4A).

ICP was then measured overnight between 2400 hours and 0700 hours on the first day of dosing (Supp. table 8, figure 4B). ICP is observed to rise progressively overnight in IIH.[25] In the placebo arm the ICP rose overnight as expected by 3.1 (4.1) mmHg, p=0.13. In the exenatide arm, the overnight rise in ICP was supressed to 0.1 (3.2) mmHg, p=0.97. There was a significant difference in the ICP measurement between the exenatide and placebo arm at the last reading of the night (0600-0700 hrs, ICP difference between arms was 5.0 (2.5) mmHg (mean (SD)) (equivalent to 6.8 (3.4) cm CSF), p=0.04).

Dual energy x-ray absorptiometry

We determined that IIH patients had a similar fat mass, lean mass and android-gynoid ratio in those treated with exenatide as compared to those on placebo with no significant differences detected at 12 weeks (Supp. table 9).

DISCUSSION

IIH:Pressure is the first randomised controlled trial comparing the efficacy of the GLP-1 receptor agonist exenatide, with placebo to reduce ICP in patients with active IIH. We have found a significant and clinically meaningful reduction in ICP in the treatment arm as compared to the placebo arm both acutely and after 12 weeks of dosing. The drug was safe and well-tolerated. This trial establishes the successful translation of pre-clinical data into humans and is the first to demonstrate a new drug treatment for IIH that significantly reduces ICP in IIH.

The hallmark of IIH is raised ICP which causes headaches and visual loss (through compression of the optic nerve and papilloedema).[10, 21, 26] Therefore, to evaluate the efficacy of exenatide the primary outcome for this trial was chosen as ICP.[27] A significant reduction in ICP was seen acutely at 2.5 hours of -4.2mmHg (equivalent to -5.7 cmCSF), which corresponds to peak

exenatide serum levels. The reduction in ICP was also noted at 24 hours (reduction of 4.7 mmHg (equivalent to 6.4 cmCSF)) (Table 1, figure 2). Other drugs (used off-label) to treat IIH have not been shown to reduce ICP within the first 24 hours of administration in patients. IIH patients can deteriorate rapidly (over days)[28] and hence a drug with rapid onset of action is clinically advantageous for IIH. A drug treatment that can rapidly reduce ICP is also of potential relevance for other conditions characterised by raised ICP such as following traumatic brain injury and stroke.

A significant reduction in ICP was also noted after prolonged dosing at 12 weeks (-4.1 mmHg equivalent to -5.6 cmCSF) (Table 1, figure 2), demonstrating durability of dosing. The minimal clinically important change in ICP in those with IIH has yet to be determined.[27] There have been four previous randomised control trials in IIH[12, 29-31] and one prospective crossover trial.[13] Four of these have utilised ICP as an outcome measure, with the magnitude of treatment effect between trial arms ranging from 5.9 cmCSF (acetazolamide and diet);[30] −6.0 (1.8) (by bariatric surgery);[12] and -6.2 cmCSF (through low calorie diet).[13] The efficacy in these studies is akin to what we have observed following treatment with exenatide for 3 months (-5.6 cmCSF).

Headache is a key disabling feature for IIH patients and listed in the top 10 priority areas for research by patient groups.[24] Headache is also a key determinant for the significantly reduced quality of life in IIH.[20] In this trial, whilst not powered to evaluate secondary outcome measures, there was a significant reduction in monthly headache days between baseline and 12 weeks amongst those patients taking exenatide (-7.7 days); those in the placebo arm did not have any significant improvement (-1.5 days) (Supp. table 2, figure 4). This is likely to be important given that a reduction in monthly headache of 1.5-2 days is regarded as meaningful in chronic migraine randomised controlled trials.[32-35] This likely reflects the reduction in ICP, as headache in IIH, whist complex, has been noted to correlate with ICP.[21] A trend to reduction in headache analgesic use, amongst those in the exenatide arm, was also recorded. Headache outcomes may show more benefit over a longer trial duration, as during the relatively short time horizon of this trial other factors may also have contributed to headache such as medication overuse and opiate use which occur in approximately one third of IIH patients.[36]

There was a significant improvement in visual acuity between the trial arms at 12 weeks (Supp. table 2, figure 3). In this trial, the magnitude of change (5 letters) was equivalent to a line on the visual acuity chart. In other ocular diseases a change of > 5 letters would have > 90% probability of being a real change.[37] Changes in visual acuity of 5 letters have been noted previously in a prospective crossover cohort study evaluating a weight loss intervention where there was a reduction of ICP by -6.2 cmCSF.[38] It is likely that the improvement in visual acuity found here may be related to resolution of the hyperopic shift associated with raised ICP and papilloedema.

Weight loss has been shown to reduce ICP in IIH.[12, 13] In this study, there was no significant reduction in body weight at 12 weeks in the treatment arm, which implies that the reduction in

ICP was highly likely to have been mediated by a reduction in CSF secretion, the mechanism demonstrated in pre-clinical studies, rather than through weight loss.[7] Additionally, the significant reduction in ICP noted at the early time points of 2.5 hours and 24 hours would have been too premature to be modulated by weight loss. GLP-1 receptor agonists such as exenatide can increase satiety and promote weight loss, but this is generally in a context of a concurrent low calorie diet.[39]

Exenatide is widely used to treat type 2 diabetes and has an established long-term safety record (licensed in 2005).[40, 41] In this trial exenatide was safe and well-tolerated, with no withdrawals due to drug adverse effects. This is relevant as the drug predominantly used off-label for IIH, acetazolamide, can be poorly tolerated. In a previous randomised controlled trial 48% of patients withdrew over a three month period, due to adverse effects.[42] Nausea is a known side effect of GLP-1 receptor agonists,[40, 41] and was predicted to occur in those IIH patients taking exenatide. In this trial 7 patients experienced nausea related to exenatide, but this settled over the first week. The nausea may, in part, be explained by the exenatide pharmacokinetic profile with high peak levels noted twice a day with twice daily Byetta dosing.[43] Our pharmacokinetic data illustrated highest serum levels at 2.5 hours post-dose in keeping with the established literature on Byetta. Anti-drug antibodies were detected in two participants. The clinical relevance of this is not determined; however, anti-drug antibodies have not been shown to impact drug effects in diabetes.[44] IIH is known to be a disease of insulin resistance,[45] and therefore exenatide's insulin sensitizing effects may have additional benefits in this population.

This is the first trial, to our knowledge, to utilise telemetric intracranial monitoring to measure ICP in IIH. Patient input into the trial design advocated for telemetric ICP monitoring over multiple lumbar punctures to facilitate data validity and reduce patient discomfort from multiple lumbar punctures. This has permitted detailed characterisation of ICP changes and the ability to measure ICP for prolonged periods over several weeks without further invasive procedures.[46] This technology has led to the accurate demonstration of ICP lowering both with single dosing and with repeated dosing. The intracranial telemetric catheters were safe, with only one failing to register by 12 weeks.

This study has several limitations. As an early phase study, it was powered to the primary endpoints of ICP reduction with single and repeated dosing. Thus, the study was underpowered to detect differences in patient centred outcomes and the secondary clinical endpoints such as headache and visual field perimetry. Powering the study for those endpoints would have required a large increase in number of participants, however, telemetric ICP monitors would not be feasible in large trial cohort. No stratification was used at randomisation, adding to the generalisability of the study; however, groups were unmatched for baseline headache days and visual field perimetry. Additionally, patients with minimal visual field defects were not excluded as in prior studies thus making the study more clinically representative, but visual effects more difficult to detect due to the ceiling effect of the measurement.

The results of this study may have wide reaching implications for many other diseases of raised ICP as the drug does not target the specific pathogenesis of IIH, but CSF secretion. Given the tolerability of exenatide and its direct and early effect on ICP, it may be beneficial in other conditions such as hydrocephalus, traumatic brain injury, raised ICP in stroke and meningitis, and space flight associated neuro-ocular syndrome. In addition, GLP-1 receptor agonists have been shown to demonstrate neuro-protective properties and hence may have additional benefits in conditions such as traumatic brain injury.[47]

We had previously identified a novel pathway to modulate ICP in an animal model.[7] This pre-clinical work has now been translated to a population of patients with raised ICP due to IIH. The data demonstrated the efficacy of exenatide to significantly lower ICP and improve clinically relevant outcome measures of monthly headache days and visual acuity. A new efficacious therapy is a clear unmet patient need,[24] and this is the first trial of a new drug treatment for IIH that significantly reduces ICP. The data presented here supports further evaluation of exenatide in a large randomized controlled trial, powered to evaluate clinically relevant outcome measures.

MATERIALS AND METHODS

Trial Design and Oversight

The trial was a prospective, randomised, parallel group, placebo-controlled trial in women with active IIH. Patients with a diagnosis of active IIH were identified and recruited from a single tertiary referral hospital (University Hospitals Birmingham NHS Foundation Trust). This study was approved by the West Midlands - Solihull Research Ethics Committee (17/WM/0179) and all subjects provided written informed consent according to Declaration of Helsinki principles. The trial was registered with ISTCRN (12678718).

Participants

Women aged 18-60 years who met the diagnostic criteria for IIH were recruited.[48] All had normal brain imaging, including magnetic resonance venography or computed tomography venography (apart from radiological signs of raised ICP). All eligible patients had active IIH (optic nerve head swelling in at least one eye and ICP >25cmCSF). Those with significant co-morbidities, prior CSF diversion procedures, those currently using GLP-1 receptor agonists or DPP-4 inhibitors or taking drugs that were thought to reduce ICP were excluded. Those taking drugs that might influence ICP discontinued these at least a month prior to enrolment. Pregnant patients or those planning pregnancy were excluded, urine HCG was checked at each study visit. Detailed enrolment criteria are provided in the Supplementary table 10.

Assessments

Following enrolment, a 28-day headache diary was completed (capturing monthly headache days (MHD), headache severity (0-10 numerical rating sale (NRS)), monthly analgesia days). A telemetric intracranial pressure catheter (Raumedic, Germany) was implanted prior to the baseline visit.

At baseline, medical history, examination (including blood pressure and heart rate) and body mass index (BMI) (calculated using the formula BMI = (weight (kg) / height (m)^2) were recorded and a urine pregnancy test performed. Visual assessments included LogMAR visual acuity and intraocular pressure as measured with the iCare IC200 (Main-line, UK); perimetric mean deviation (PMD) using the Humphrey visual field analyser (24-2 Swedish Interactive Threshold Algorithm (SITA) standard test pattern using a size III white stimulus). Papilloedema was confirmed on a dilated slit lamp examination by a neuro-ophthalmologist. It was quantified by spectral domain optical coherence tomography (OCT; Spectralis, Heidelberg Engineering, Germany) using the global peripapillary retinal nerve fibre layer. Patient reported outcome measures were assessed (Headache Impact Test -6 (HIT-6)[49] and 36-item short from survey (SF-36) Rand version).[50] Assessments were repeated at 12 weeks. Drug compliance was monitored based on the remaining exenatide in the pen injector device.

Blood samples were collected at baseline pre-dose and post-dose at 2.5, 6, 11, 22 and 24 hours, at 2 weeks (pre and 2.5 hours post-dose), and 12 weeks (pre and 2.5 hours post-dose), to evaluate safety bloods, pharmacokinetics and antidrug antibodies.

ICP was recorded using a transdermal telemetric ICP monitoring system (Raumedic, Germany) at baseline, 2.5 hours, 24 hours and 12 weeks. In the planned exploratory analysis ICP was measured continuously for the first 2.5 hours after dosing and then between 0000hrs and 0700hours overnight following the first dose. ICP data was collected at a frequency of 5Hz and the mean ICP was calculated from each 30 minutes of continuous ICP monitoring over the first 2.5hrs and each hour overnight. The schedule of assessments is detailed in supplementary table 11.

Body composition

Dual energy x-ray absorptiometry (DEXA) was performed using a total-body scanner (QDR 4500; Hologic, Bedford, MA, USA), as previously described[51, 52] on a subset of patients. The scans were conducted by a clinical scientist and trained radiographer. Patients with metal prosthetics or implants were included, and tissue overlying the prosthesis was excluded from analysis. Scans were checked for accuracy of fields of measurement. Regional fat mass was analysed as described previously.[51, 52] The precision of total fat mass measures in terms of coefficients of variation (CV) was less than 3%, and for regional fat analyses it was less than 5%. All subjects were analysed on the same DEXA scanner.

Randomization and Study Treatment

Participants were randomized in a 1:1 ratio to either active treatment with exenatide (Byetta) or placebo using a computer-generated randomization list generated by the Birmingham Clinical Trials Unit. Treatment allocation was blinded to patient and investigators. A double check of allocation was performed by an unblinded nurse and pharmacist. The first dose was a loading dose of subcutaneous exenatide 20mcg or equivalent volume of subcutaneous 0.9% saline

placebo. Subjects were then dosed for 12 weeks (self-administered at home) with either subcutaneous exenatide 10mcg or equivalent volume of placebo twice daily.

Blood analysis

The following fasted bloods were processed at the hospital laboratory: (creatinine (μmol/L), alanine aminotransferase (ALT) (IU/L), high-density lipoproteins (HDL) (mmol/L), total cholesterol (mmol/L), triglycerides (TG) (mmol/L), haemoglobin A1c (HbA1C) (mmol/mol)). Samples not analysed immediately were centrifuged (10 minutes at 1500 g at 4°C) aliquoted and stored at -80 °C. All samples only underwent a single freeze-thaw cycle.

Fasting insulin and HOMA2-IR

Fasting insulin (Mercodia, Uppsala, Sweden) was measured using a commercially available assay, according to the manufacturer's instructions. Homeostasis model assessment of insulin resistance (HOMA2-IR) was calculated using the program HOMA calculator v2.2.3. [53]

Pharmacokinetics

Exenatide concentration was evaluated by Enzyme-Linked Immunosorbent Assay (ELISA). ELISA was performed on serum samples from 7 patients receiving the active drug. Serum was collected at 10 time points; baseline, 2.5 hours, 6 hours, 11 hours, 22 hours and 24 hours, week 2 at baseline and 2.5 hours post dose, week 12 at baseline and 2.5 post dose. An exenatide fluorescent ELISA (Phoenix Pharmaceuticals Inc) was used. This was a competitive enzyme immunoassay, wherein the primary antibody is competitively bound by either a biotinylated peptide or the targeted peptide in samples. All samples were run in triplicate. The assay was performed according to manufacturer's protocol.[54]

Anti-Exendin-4 antibody levels in serum

In the light of reports of the development of anti-exenatide antibody in human studies administering exenatide in type 2 diabetes mellitus[44, 55] (with anti-exenatide titres peaking between 6-22 weeks), as well as their presence in preclinical studies,[54, 56] we investigated whether such antibodies developed in our clinical study. As the trial lasted for a period of 12 weeks, we evaluated serum anti-exendin-4 antibody levels in 16 patients at baseline (prior to exenatide treatment), and at week 2 and 12 of the trial by employing a previously developed sandwich ELISA.[56] All week 2 and 12 serum samples were obtained before exenatide administration for the day, and serial dilutions of each serum samples were used in the ELISA. A brief protocol for the ELISA is as following: plates were coated with exenatide (exendin-4) (2 µg/ml concentration in coating buffer (AnaSpec Inc., Fremont, CA, USA)) at 4°C overnight. Thereafter, following blocking and washing steps, standards (mouse monoclonal anti-exendin-4 antibody (Abcam (ab23407), Waltham, MA, USA) and unknown samples with serial dilutions were added to the plate and incubated at room temperature for 1 hr. After washing, biotinylated-exendin-4 (2 µg/ml concentration (AnaSpec Inc., Fremont, CA, USA)) was added and followed by washing and SA-HRP detection (KPL, Gaithersburg, MD, USA). The titres of the anti-

exenatide antibody within the samples were then estimated by serial dilution of the serum (to a maximum dilution of 1:125).

Outcomes Measure

The primary outcome was ICP at 2.5hrs, 24hrs and 12 weeks post drug administration. ICP was recorded with p-Tel telemetric intracranial pressure catheter and MPR-1 reader (Raumedic, Germany). ICP was recorded continuously for 30-minute periods at specified timepoints in a standardised supine position. For the first 2.5 hours post dosing, mean ICP was calculated from each 30 minutes of continuous ICP monitoring. For the overnight recording the mean ICP was calculated from each hour of continuous ICP monitoring. ICP was sampled at 5Hz. Recordings were downloaded and analysed in Dataview version 1.2 (Raumedic, Germany). ICP was recorded in mmHg (conversion factor to cmCSF was 1.36).

Secondary outcomes included: monthly headache days, headache severity and monthly analgesia days, logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts; perimetric mean deviation (PMD) using Humphrey 24-2 Swedish Interactive Thresholding Algorithm (SITA) central threshold automated perimetry; BMI and health-related quality of life (measured by short-form (SF)-36 and HIT-6). Evaluations were at baseline 2.5 hours, 24 hours and 12 weeks (with additional blood sampling at 2 weeks).

Adverse Event Reporting

Adverse events were recorded as was drug compliance (unused medication in the injector pens documented).

Sample Size Calculation

In a study of 25 patients, Sinclair et al.[13] showed that the cross-sectional sample standard deviation of ICP is 4.9 – 5.1 cmCSF, measured at baseline and immediately before and after a longitudinal intervention (low energy diet). There are very few trials in IIH and the minimal clinically important change for LP pressure is not established and may vary with individual patients.   Seeking significance at least alpha < 0.1 and power at least 80% using equal group sizes, a total sample size of 14 patients was required, i.e. 7 patients randomised to receive active treatment and a further 7 to receive control. This calculation assumed an effect size of 6.5 cmCSF with a standard deviation of 5.1 cmCSF, the upper end of the range observed previously. Allowing for 10% drop-out, the proposed recruitment was 8 patients per arm, and 16 patients in total.

Statistical Analyses

All primary analyses (primary and secondary outcomes including safety outcomes) were evaluated by intention-to-treat (ITT) analysis. Analysis was completed on received data, with

every effort made to follow-up participants to minimize potential for bias. Final analyses were conducted after the final visit of the final patient of the main trial once the data had been cleaned and locked; then unblinded. No imputation of missing data was conducted. The analysis of visual data included data from the most affected eye at baseline as defined by PMD, analysis of intra-ocular pressure was performed on the mean average of both eyes. Statistical analysis was performed in R v4.0.0 (R Foundation for Statistical Computing, Vienna, Austria). Data were reported as means and SD (with median and interquartile range [IQR] for non-normal data), and SE and 95% confidence intervals (CI) where appropriate. Hierarchical linear regression models were used to analyse repeated measures of the primary and secondary outcomes and to estimate differences adjusted for baseline values. In these models, population-level effects (also known as fixed effects) comprised the intercept, time as a factor variable, and the 2-way interaction of treatment arm and time as a factor variable to model changing treatment effects over time. Group-level effects (also known as random effects) comprised patient-level adjustments to the intercept. The threshold for statistical significance was pre-specified at 0.1.

List of Supplementary Materials

Fig S1 to S2 for multiple supplementary figures

Tables S1 to S11 for multiple supplementary tables

References and Notes

Uncategorized References

1.   Drucker, D.J., *Biological actions and therapeutic potential of the glucagon-like peptides.* Gastroenterology, 2002. **122**(2): p. 531-44.
2.   Alvarez, E., et al., *Expression of the glucagon-like peptide-1 receptor gene in rat brain.* Journal of neurochemistry, 1996. **66**(3): p. 920-927.
3.   Carr, R.D., et al., *Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.* The Journal of clinical endocrinology and metabolism, 2010. **95**(2): p. 872-878.
4.   Rubino, D., et al., *Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.* JAMA, 2021. **325**(14): p. 1414-1425.
5.   Gutzwiller, J.-P., et al., *Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.* The Journal of clinical endocrinology and metabolism, 2004. **89**(6): p. 3055-3061.
6.   von Websky, K., C. Reichetzeder, and B. Hocher, *Physiology and pathophysiology of incretins in the kidney.* Current opinion in nephrology and hypertension, 2014. **23**(1): p. 54-60.

7. Botfield, H.F., et al., *A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus.* Science translational medicine, 2017. **9**(404): p. eaan0972.

8. Ast, J., et al., *Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics.* Nat Commun, 2020. **11**(1): p. 467.

9. Scotton, W.J., et al., *Topiramate is more effective than acetazolamide at lowering intracranial pressure.* Cephalalgia, 2018. **55**: p. 033310241877645-10.

10. Mollan, S.P., et al., *New horizons for idiopathic intracranial hypertension: advances and challenges.* Br Med Bull, 2020. **136**(1): p. 118-126.

11. Mollan, S.P., A.A. Tahrani, and A.J. Sinclair, *The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension: Body Weight.* Neurol Clin Pract, 2021. **11**(4): p. e504-e507.

12. Mollan, S.P., et al., *Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension: A Randomized Clinical Trial.* JAMA Neurol, 2021. **78**(6): p. 678-686.

13. Sinclair, A.J., et al., *Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study.* BMJ, 2010. **341**(jul07 2): p. c2701-c2701.

14. Mollan, S.P., et al., *The expanding burden of idiopathic intracranial hypertension.* Eye, 2018.

15. Adderley, N.J., et al., *Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom.* JAMA neurology, 2019. **76**(9): p. 1088-1098.

16. Mollan, S.P., et al., *Idiopathic Intracranial Hypertension: Evaluation of Admissions and Emergency Readmissions through the Hospital Episode Statistic Dataset between 2002-2020.* Life (Basel), 2021. **11**(5).

17. McCluskey, G., et al., *Meta-analysis and systematic review of population-based epidemiological studies in idiopathic intracranial hypertension.* European journal of neurology : the official journal of the European Federation of Neurological Societies, 2018. **25**(10): p. 1218-1227.

18. Wall, M. and D. George, *Idiopathic intracranial hypertension. A prospective study of 50 patients.* Brain, 1991. **114 (Pt 1A)**: p. 155-80.

19. Corbett, J.J., et al., *Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss.* Arch Neurol, 1982. **39**(8): p. 461-74.

20. Mulla, Y., et al., *Headache determines quality of life in idiopathic intracranial hypertension.* The Journal of Headache and Pain, 2015. **16**(1): p. 461.

21. Mollan, S.P., et al., *Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension.* J Headache Pain, 2021. **22**(1): p. 118.

22. Grech, O., et al., *Cognitive performance in idiopathic intracranial hypertension and relevance of intracranial pressure.* Brain Communications, 2021. **3**(3).

23. Mollan, S.P., et al., *Idiopathic intracranial hypertension: consensus guidelines on management.* J Neurol Neurosurg Psychiatry, 2018. **89**(10): p. 1088-1100.

24. Mollan, S., et al., *What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals.* BMJ Open, 2019. **9**(3): p. e026573.

25. Ogashiwa, M. and K. Takeuchi, *[Intracranial pressure changes during sleep in man].* No To Shinkei, 1983. **35**(2): p. 123-9.

26. Mollan, S.P., O. Grech, and A.J. Sinclair, *Headache attributed to idiopathic intracranial hypertension and persistent post-idiopathic intracranial hypertension headache: A narrative review.* Headache, 2021. **61**(6): p. 808-816.

27. Mollan, S.P. and A.J. Sinclair, *Outcomes measures in idiopathic intracranial hypertension.* Expert Rev Neurother, 2021. **21**(6): p. 687-700.

28. Mitchell, J.L., et al., *Telemetric monitoring in idiopathic intracranial hypertension demonstrates intracranial pressure in a case with sight-threatening disease.* Acta Neurochir (Wien), 2021. **163**(3): p. 725-731.

29. Ball, A.K., et al., *A randomised controlled trial of treatment for idiopathic intracranial hypertension.* Journal of Neurology, 2010. **258**(5): p. 874-881.

30. Wall, M., et al., *Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss.* JAMA, 2014. **311**(16): p. 1641-24.

31. Markey, K., et al., *11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial.* Brain Communications, 2020. **2**(1): p. 874.

32. Mollan, S.P., J. Hoffmann, and A.J. Sinclair, *Advances in the understanding of headache in idiopathic intracranial hypertension.* Curr Opin Neurol, 2019. **32**(1): p. 92-98.

33. Ottridge, R., et al., *Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol.* BMJ Open, 2017. **7**(9): p. e017426.

34. Tepper, S., et al., *Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.* The Lancet Neurology, 2017. **16**(6): p. 425-434.

35. Silberstein, S.D., et al., *Fremanezumab for the Preventive Treatment of Chronic Migraine.* New England Journal of Medicine, 2017. **377**(22): p. 2113-2122.

36. Mollan, S.P., J. Hoffmann, and A.J. Sinclair, *Advances in the understanding of headache in idiopathic intracranial hypertension.* Current opinion in neurology, 2019. **32**(1): p. 92-98.

37. Beck, R.W., et al., *Visual acuity as an outcome measure in clinical trials of retinal diseases.* Ophthalmology, 2007. **114**(10): p. 1804-1809.

38. Sinclair, A.J., et al., *Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study.* BMJ, 2010. **341**(jul07 2): p. c2701-c2701.

39. Buse, J.B., et al., *DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks.* Diabetes Care, 2010. **33**(6): p. 1255-1261.

40. Kolterman, O.G., et al., *Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.* Am J Health Syst Pharm, 2005. **62**(2): p. 173-81.

41. MacConell, L., et al., *Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.* Diabetes Metab Syndr Obes, 2015. **8**: p. 241-53.

42.   Ball, A.K., et al., *A randomised controlled trial of treatment for idiopathic intracranial hypertension.* J Neurol, 2011. **258**(5): p. 874-81.

43.   Kothare, P.A., et al., *Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.* J Clin Pharmacol, 2008. **48**(12): p. 1389-99.

44.   Fineman, M.S., et al., *Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.* Diabetes Obes Metab, 2012. **14**(6): p. 546-54.

45.   Westgate, C.S., et al., *Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension.* JCI Insight, 2021. **6**(10).

46.   Mitchell, J.L., et al., *Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension.* Current opinion in neurology, 2019. **32**(3): p. 422-431.

47.   Erbil, D., et al., *GLP-1's role in neuroprotection: a systematic review.* Brain Inj, 2019. **33**(6): p. 734-819.

48.   Friedman, D.I., G.T. Liu, and K.B. Digre, *Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.* Neurology, 2013. **81**(13): p. 1159-1165.

49.   Kosinski, M., et al., *A six-item short-form survey for measuring headache impact: the HIT-6.* Qual Life Res, 2003. **12**(8): p. 963-74.

50.   Hays, R.D. and L.S. Morales, *The RAND-36 measure of health-related quality of life.* Annals of Medicine, 2009. **33**(5): p. 350-357.

51.   Tomlinson, J.W., et al., *Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.* Diabetes, 2008. **57**(10): p. 2652-60.

52.   Stewart, P.M., et al., *Cortisol metabolism in human obesity: impaired cortisone-->cortisol conversion in subjects with central adiposity.* J Clin Endocrinol Metab, 1999. **84**(3): p. 1022-7.

53.   Levy, J.C., D.R. Matthews, and M.P. Hermans, *Correct homeostasis model assessment (HOMA) evaluation uses the computer program.* Diabetes Care, 1998. **21**(12): p. 2191-2.

54.   Li, Y., et al., *Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon.* Sci Rep, 2019. **9**(1): p. 17208.

55.   Peng, H., L.L. Want, and V.R. Aroda, *Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.* Curr Diab Rep, 2016. **16**(5): p. 44.

56.   Chen, S., et al., *Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.* Sci Rep, 2018. **8**(1): p. 10722.

Acknowledgments:

Figures

Fig. 1. Consort diagram. Consort diagram describing the numbers and disposition of study subjects.

Fig. 2. Primary outcomes. Mean change (SEM) of ICP in a) ICP at 2.5 hours; B) ICP at 24 hours ; C) ICP at 12 weeks. *P<0.1 (significant level set at p<0.1). Diurnal variability in ICP reflected in changes in ICP readings at different times of day observed in the placebo arm.

Fig. 3. Monthly headache days and analgesia, Visual acuity and BMI. Mean change (SEM) at 12 weeks of a) Monthly headache days, b) Monthly analgesia days, c) Visual acuity measured by logMAR and d) Body mass index (BMI). *P<0.1 (significant level set at p<0.1).

Fig. 4. First 2.5hrs, overnight ICP. Mean ICP (SEM) by arm measured a) continuously over 2.5hrs after dose and b) hourly overnight. *P<0.1 (significant level set at p<0.1).

Funding:

This study was funded by Enterprising Birmingham, University of Birmingham, UK, from 1st August 2016. Further funding was sought and from 1st August 2019 an investigator led grant was obtained from Invex therapeutics.

JLM was funded by the Ministry of Defence for the duration of the study.

AY was funded by an Association of British Neurologists and Guarantors of the Brain fellowship.

OG was funded by Brain research UK.

YL and NHG are supported by the Intramural Research Program, National Institute on Aging, NIH (AG000333).

AJS was funded by a National Institute for Health Research (NIHR) clinician scientist fellowship (NIHR-CS-011-028) and the Medical Research Council, UK (MR/K015184/1) for the duration of the study. AJS is funded by a Sir Jules Thorn Award for Biomedical Science. The view expressed are those of the authors and not necessarily those of the UK National Health Service, MoD, NIHR, or the UK department of Health and Social Care.

Role of Funder/Sponsor: The MoD, NIHR, MRC and Invex Therapeutics had no role in the design or conduct of the study; no role in collection, management or interpretation of the data; writing of the manuscript; and no role in the decision to submit the manuscript for publication.

Author contributions:

Conceptualization: AS
Methodology: GT, SPM, JLM, AY, AS
Investigation: JLM, AY, KB, AS
Visualization: HL, JW, OG, ZA, AS

Exenatide/antibody: YL, NHG
Funding acquisition: AS,
Project administration: AS
Supervision: SPM, AS
Writing – original draft: JLM, SPM, AS
Writing – review & editing: SPM, AS

Competing interests:

JLM was funded by the UK Ministry of Defence for the duration of the study.

OG reports scientific consultancy fees from Invex therapeutics (2020).

AY reports receiving speaker fees from Teva, UK, outside the submitted work.

KB works for UCB.

Professor Mollan reports other Invex Therapeutics, other Heidelberg engineering during the conduct of the study; other from Chugai-Roche Ltd, other from Janssen, other from Allergan, other from Santen, other from Roche, other from Neurodiem, outside the submitted work.

Professor Sinclair reports personal fees from Invex therapeutics in her role as Director with stock holdings, during the conduct of the study (since 28.06.2019); other from Allergan, Novartis, Cheisi and Amgen outside the submitted work.

All other authors declare no competing interests.

Data and materials availability:

Anonymized individual participant data will be made available along with the trial protocol and statistical analysis plan. Proposals should be made to the corresponding author and will be reviewed by the Data Sharing Committee in discussion with the Chief Investigator. A formal Data Sharing Agreement may be required between respective organizations once release of the data is approved and before data can be released.